PPCM Observational Study (Peripartum Cardiomyopathy)

Overview

The purpose of this study is to examine the clinical treatment of patients diagnosed with peripartum cardiomyopathy complicated by cardiogenic shock.

Full Title of Study: “Observational Study for Outcomes for Participants With Cardiogenic Shock and Peripartum Cardiomyopathy”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 31, 2022

Detailed Description

This single-site, virtual, longitudinal, observational study will investigate two cohorts (study groups) by enrolling a total of ten participants, five in each cohort. The two cohorts include individuals who received mechanical circulatory support (specifically the IMPELLA® device) compared to individuals who did not receive mechanical circulatory support for treatment of their PPCM complicated by cardiogenic shock index event. The duration of enrollment for each participant is about 5 months. It is anticipated that the trial will be complete in 12 months. Participant engagement to the study will be self-initiated. Under the guidance and support of Medical College of Wisconsin research coordinator, participants will directly access the study REDCapTM database for enrollment and follow-up data entry for this study. The research coordinator will obtain and abstract participant medical records documenting the event.

Interventions

  • Device: Clinical placement of a temporary IMPELLA® mechanical circulatory support device.
    • Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.

Arms, Groups and Cohorts

  • Individuals Receiving Mechanical Circulatory Device Support
    • Individuals receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
  • Individuals Without Mechanical Circulatory Device Support
    • Individuals not receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.

Clinical Trial Outcome Measures

Primary Measures

  • Description of the Long-term Clinical Course of Patients with Peripartum Cardiomyopathy complicated by cardiogenic shock.
    • Time Frame: From onset of event through 90 days after participant enrollment.
    • The retrospective and prospective data collected from study participants will report clinical treatments required to treat the diagnosis of peripartum cardiomyopathy complicated by cardiogenic shock.

Participating in This Clinical Trial

Inclusion Criteria

Females:

  • age ≥ 18 years old at the time of entry into the study – who have capacity to provide consent for study participation – with self-reported PPCM complicated by cardiogenic shock – individuals should have US citizenship – index event occurring within the continental United States. Exclusion Criteria:

  • lack of medical records supporting pregnancy, peripartum cardiomyopathy or cardiogenic shock by study definition – inability of participant to provide informed consent

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medical College of Wisconsin
  • Collaborator
    • Abiomed Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Sarah Thordsen, Assistant Professor Cardiovascular Medicine – Medical College of Wisconsin
  • Overall Official(s)
    • Sarah Thordsen, MD, Principal Investigator, Medical College of Wisconsin
  • Overall Contact(s)
    • Susan K. Mauermann, RN, 414-955-6749, smauerma@mcw.edu

References

McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, Modi K, Alexis JD, Ramani GV, Semigran MJ, Haythe J, Markham DW, Marek J, Gorcsan J 3rd, Wu WC, Lin Y, Halder I, Pisarcik J, Cooper LT, Fett JD; IPAC Investigators. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 Aug 25;66(8):905-14. doi: 10.1016/j.jacc.2015.06.1309.

Kolte D, Khera S, Aronow WS, Palaniswamy C, Mujib M, Ahn C, Jain D, Gass A, Ahmed A, Panza JA, Fonarow GC. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc. 2014 Jun 4;3(3):e001056. doi: 10.1161/JAHA.114.001056.

Doerr M, Grayson S, Moore S, Suver C, Wilbanks J, Wagner J. Implementing a universal informed consent process for the All of Us Research Program. Pac Symp Biocomput. 2019;24:427-438.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.